The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications.

Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance.

Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAIN-MAINTAIN Phase 3 trial of orforglipron.

The Phase 3 study evaluated orforglipron for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Novo Nordisk A/S‘ (NYSE:NVO) Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to receive orforglipron or placebo.

Data

At one year, ...